European Competition Law Review: The Competition Appeal Tribunal’s judgment in Pfizer/Flynn – when is a high price unfair?

Managing Director Mat Hughes co-authored this analysis of the Competition Appeal Tribunal’s (CAT) judgment in the excessive pricing case, Pfizer/Flynn.